Lymphoma Newswire (Page 5)

Lymphoma Newswire (Page 5)

Comprehensive Real-Time News Feed for Lymphoma. (Page 5)

Results 81 - 100 of 60,967 in Lymphoma

  1. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Monday Dec 11 | Business Wire

    ... the Combination of ADCETRIS (Brentuximab Vedotin) and Opdivo (Nivolumab) in Relapsed or Refractory Hodgkin Lymphoma )--Seattle Genetics and BMS Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS and Opdivo in ...

    Comment?

  2. Inspirational Athlete: Farrell grid player says cancer made him strongerRead the original story w/Photo

    Monday Dec 11 | SILive.com

    Monsignor Farrell High School senior Dan Bentivegna was never the biggest or strongest player on the Lions' football team, but he's no stranger to overcoming obstacles. In February of 2008, when Bentivegna was just seven years old, he was diagnosed with a stage 4 case of non-Hodgkins Burkitt's Lymphoma in which he had tumors in his lower intestines.

    Comment?

  3. CTL019 More Cost Effective in Pediatric Patients With Acute Lymphoblastic LymphomaRead the original story w/Photo

    Monday Dec 11 | The American Journal of Managed Care

    Two abstracts at the 59th Annual Meeting of the American Society of Hematology in Atlanta, Georgia found that CTL019 shows promising potential in providing significant benefit and cost effectiveness for pediatric and young adult patients with B-cell acute lymphoblastic leukemia in both the United States and the United Kingdom. According to 2 studies presented at the 59th Annual Meeting & Exposition of the American Society of Hematology in Atlanta, Georgia, CTL019 shows promising potential in providing significant benefit and cost effectiveness for pediatric and young adult patients with B-cell acute lymphoblastic leukemia .

    Comment?

  4. Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASHRead the original story w/Photo

    Monday Dec 11 | The American Journal of Managed Care

    ... development of myeloid malignancies.6 Of the 401 patients who received autologous stem-cell transplants for their lymphoma treatment, patients with CHIP had significantly lower 10-year overall survival (30.4%) compared with patients without CHIP ...

    Comment?

  5. St. Louis residents use plants to cope with their illnessesRead the original story w/Photo

    Monday Dec 11 | The Columbian

    ... ever going to be in." Thomas Brouk, 68, has received regular anti-cancer drug infusions since January to treat his lymphoma. Brouk, who grew up on a farm in Arnold, said he didn't have electricity until 1978 and had always had a special connection ...

    Comment?

  6. Roswell Park Hematology Experts Sharing New Research in ASH 2017 Podium PresentationsRead the original story w/Photo

    Monday Dec 11 | Newswise

    ... of Children's Oncology Group data regarding more than 2,000 children and adolescents with newly diagnosed Hodgkin lymphoma. While many studies suggest that low socioeconomic status and black or Hispanic race/ethnicity are associated with reduced ...

    Comment?

  7. Using Emojis to Assess Cancer Patients' Quality of LifeRead the original story w/Photo

    Monday Dec 11 | PsychCentral

    ... patient-reported outcome measures in cancer patients," said Dr. Thompson. Researchers recruited 115 patients with lymphoma and multiple myeloma at Mayo Clinic with expected life spans of less than five years and who owned an iPhone 5 or later. All ...

    Comment?

  8. Cancer Genetics advances understanding of immune response and...Read the original story w/Photo

    Monday Dec 11 | GlobeNewswire

    ... hybridization (ISH), using RNAscopeA 1 approach to determine the expression of PD-L1 in diffuse large B-cell lymphoma (DLBCL) cells, a particularly aggressive form of lymphoma. Although the two modalities demonstrated relative concordance related to ...

    Comment?

  9. FDA Accepts Supplemental Biologics License Application (sBLA),...Read the original story

    Monday Dec 11 | Customer Interaction Solutions

    FDA Accepts Supplemental Biologics License Application , Assigns Priority Review to Merck's KEYTRUDA for Treatment of Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma FDA Accepts Supplemental Biologics License Application , Assigns Priority Review to Merck's KEYTRUDA for Treatment of Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Merck , known as MSD outside the United States and Canada, today announced findings from the phase 2 KEYNOTE-170 trial investigating the use of KEYTRUDA , the company's anti-PD-1 therapy, in the cohort of patients with relapsed or refractory primary mediastinal large B-cell lymphoma , a type of non-Hodgkin lymphoma.

    Comment?

  10. TG Therapeutics, Inc. Announces Preclinical & Clinical Data...Read the original story

    Monday Dec 11 | Customer Interaction Solutions

    ... Chronic Lymphocytic Leukemia (CLL) a 53% ORR for single agent TGR-1202 in relapsed/refractory Follicular Lymphoma (FL) KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) In Patients with Chronic ...

    Comment?

  11. Juno Therapeutics and Celgene Corporation Release Additional Data...Read the original story w/Photo

    Monday Dec 11 | Business Wire

    ... (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (NHL) in a presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition. "We are highly ...

    Comment?

  12. BOK promotes chemical-induced hepatocarcinogenesis in miceRead the original story

    Monday Dec 11 | Cell Death and Differentiation

    ... in human cancers [ 26 ]. Loss of Bok did, however, not affect the outcome of EA -myc transgene-induced preB-/B-cell lymphoma in the mouse [ 21 ]. The same study also showed that endogenous BOK levels are very low in lymphocytes, whereas generally ...

    Comment?

  13. Bcl-2 on the brink of breakthroughs in cancer treatmentRead the original story

    Monday Dec 11 | Cell Death and Differentiation

    Thank you for visiting nature.com. You are using a browser version with limited support for CSS.

    Comment?

  14. AML study reports high response rates with combination targeted therapyRead the original story w/Photo

    Sunday Dec 10 | EurekAlert!

    ... options for patients with relapsed and/or refractory AML are limited." Venetoclax, which inhibits the B-cell lymphoma protein (BCL-2) that makes cancer cells resistant to therapy, was previously FDA-approved for treatment of chronic lymphocytic ...

    Comment?

  15. Genentech's Lymphoma Drug Combo Wows in Mid-Stage TrialRead the original story w/Photo

    Sunday Dec 10 | BioSpace

    Dec. 10, 2017 14:00 UTC Phase II Data Showed Genentech's Investigational Polatuzumab Vedotin Plus Bendamustine and Rituxan Increased Complete Response Rates Compared to BR Alone in Previously Treated Aggressive Lymphoma - Polatuzumab vedotin combination demonstrated improvements across multiple efficacy measures compared to BR alone in relapsed or refractory diffuse large B-cell lymphoma - SOUTH SAN FRANCISCO, Calif.-- -- Genentech , a member of the Roche Group , announced today positive results from the randomized Phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus RituxanA against BR alone in people with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for hematopoietic stem cell transplant.

    Comment?

  16. Top 5 Massachusetts Biotechs That Jumped at Least 250% in 2017Read the original story w/Photo

    Sunday Dec 10 | BioSpace

    ... DUO study of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL/small lymphocytic lymphoma (SLL)) at the American Society of Hematology (ASH) 2017 Annual Meeting in Atlanta. "In the Phase III DUO study, oral ...

    Comment?

  17. Novel immunotherapy brings new hope for cancer patientsRead the original story

    Nov 12, 2017 | Newkerala.com

    New York, Dec 11 : Researchers, led by one of Indian-origin, have developed a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells. The novel treatment involves the recently approved CD19-targeting chimeric antigen receptor T cell therapy for patients with aggressive large B-cell lymphoma -- blood cancers -- who had failed prior chemotherapy and stem cell transplantation.

    Comment?

  18. Mayo Clinic researchers find emojis to be helpful in assessing patients' quality of lifeRead the original story w/Photo

    Monday Dec 11 | Medical News

    ... patient-reported outcome measures in cancer patients," says Dr. Thompson. Researchers recruited 115 patients with lymphoma and multiple myeloma at Mayo Clinic with expected life spans of less than five years and who owned an iPhone 5 or later. All ...

    Comment?

  19. Car T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patientsRead the original story w/Photo

    Sunday Dec 10 | Medical News

    In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor T cell therapy Kymriah demonstrated long-lasting remissions in non-Hodgkin's lymphoma patients. Results from a global, multisite trial will be presented today at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta .

    Comment?

  20. ADC Therapeutics Announces Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-301Read the original story

    Sunday Dec 10 | Customer Interaction Solutions

    Therapeutics , an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-301 in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology Annual Meeting in Atlanta, USA.

    Comment?